The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis.
NCT02717650
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Melbourne, Victoria, Australia
View Trial DetailsNCT Number: NCT01116414
The purpose of this study is to develop an integrated view of molecular mechanisms underlying CF lung disease severity.
Looking for future studies?
Notify Me15 year and older
All sexes
Observational
Johns Hopkins University, Baltimore, Maryland, United States
BACKGROUND:
Cystic fibrosis (CF) is a recessive genetic disorder caused by mutations in CF transmembrane conductance regulator (CFTR) gene. CF has multi-organ involvement, but respiratory disease is the major cause of morbidity and mortality. The median age of survival in CF is only 37 years, but there is a broad range of disease severity in the lung, even among patients with identical CFTR genotypes, including deltaF508 homozygotes.
DESIGN NARRATIVE:
This project holds great promise for defining a robust molecular phenotype for CF lung disease, which relates to prognosis, and new targets for therapy. By using a large and well-defined population of deltaF508 homozygotes who also have whole genome single nucleotide polymorphism (SNP) data, and by studying gene expression across the whole transcriptome in a large number of samples of two relevant tissues (respiratory epithelium and transformed lymphocytes), we will be uniquely positioned to develop an integrated view of molecular mechanisms underlying CF lung disease severity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
University of North Carolina, Chapel Hill
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02717650
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Melbourne, Victoria, Australia
View Trial DetailsNCT05752019
Bacterial Infections, Bacterial Infections and Mycoses
Rotterdam, South Holland, Netherlands
View Trial DetailsNCT05251467
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Nottingham, United Kingdom
View Trial DetailsNCT05253859
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Nottingham, United Kingdom
View Trial Details